Immunosuppression Does Not Reduce Anti-tumor Efficacy _JACC.pdf (271.77 kB)
Download file

Immunosuppression Does Not Reduce Antitumor Efficacy

Download (271.77 kB)
journal contribution
posted on 15.02.2019, 12:55 by TH Cao
I read with great interest the paper by Mahmood et al. The authors conducted a very valuable and interesting study of 35 patients with immune checkpoint inhibitor (ICI)-associated myocarditis compared with 105 ICI-treated patients without myocarditis in a multicenter registry with 8 sites. The study found that myocarditis developed at a median of 34 days in patients receiving ICIs for the treatment of cancer. Moreover, the authors indicated that there were higher serum troponin levels and major adverse cardiac event rates with the use of lower steroid doses; higher steroid doses were associated with lower serum troponin levels and major adverse cardiac event rates in ICI-treated patients with myocarditis.

Funding

Dr. Cao is funded by the John and Lucille van Geest Foundation and the National Institute for Health Research Leicester Biomedical Research Centre.

History

Citation

J Am Coll Cardiol, 2018, 72 (6), p. 701

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Cardiovascular Sciences

Version

AM (Accepted Manuscript)

Published in

J Am Coll Cardiol

Publisher

Elsevier for American College of Cardiology

eissn

1558-3597

Acceptance date

09/04/2018

Copyright date

2018

Available date

07/08/2019

Publisher version

https://www.sciencedirect.com/science/article/pii/S0735109718350769?via=ihub

Notes

The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.

Language

en

Usage metrics

Categories

Keywords

Exports